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ABSTRACT
Background: Disturbances in rest–activity rhythm are prominent and
disabling symptoms in Alzheimer’s disease (AD). Nighttime sleep is severely
fragmented and daytime activity is disrupted by multiple napping episodes.
In most institutional environments, light levels are very low and may
not be sufficient to enable the circadian clock to entrain to the 24-hour
day. The purpose of this randomized, placebo-controlled, clinical trial was to
test the effectiveness of morning bright light therapy in reducing rest–activity
(circadian) disruption in institutionalized patients with severe AD.
Method: Subjects (n= 46, mean age 84 years) meeting the NINCDS-ADRDA
(National Institute of Neurological and Communicative Disorders and Stroke –
the Alzheimer’s Disease and Related Disorders Association) AD diagnostic
criteria were recruited from two large, skilled nursing facilities in San Francisco,
California. The experimental group received one hour (09:30–10:30) of bright
light exposure (≥ 2500 lux in gaze direction) Monday through Friday for
10 weeks. The control group received usual indoor light (150–200 lux).
Nighttime sleep efficiency, sleep time, wake time and number of awakenings and
daytime wake time were assessed using actigraphy. Circadian rhythm parameters
were also determined from the actigraphic data using cosinor analysis and
nonparametric techniques. Repeated measures analysis of variance (ANOVA)
was used to test the primary study hypotheses.
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Results and conclusion: Although significant improvements were found in
subjects with aberrant timing of their rest–activity rhythm, morning bright light
exposure did not induce an overall improvement in measures of sleep or the rest–
activity in all treated as compared to control subjects. The results indicate that
only subjects with the most impaired rest–activity rhythm respond significantly
and positively to a brief (one hour) light intervention.
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Introduction
Sleep disturbances are one of the primary reasons for Alzheimer’s disease (AD)
patients to be institutionalized (Hope et al., 1998; Yaffe et al., 2002). These
disturbances negatively impact quality of life for both patients and caregivers.
Neuroanatomical and neurochemical alterations and deterioration that underlie
the AD process, genetic factors (e.g. state–trait variability, apolipoprotein E
(APOE) carrier status), institutionalization, and decreases in external zeitgebers
that influence circadian rhythms (e.g. bright light) probably all contribute to the
etiology of the rest–activity disruptions (Bliwise et al., 1995; Yesavage et al., 2002;
2003; 2004). Disruptions include severely fragmented nighttime sleep (increased
number and duration of awakenings), decreased total nighttime sleep time,
and increased daytime sleep. Pharmacologic treatment for sleep disruption has
proved to be only minimally effective and is often associated with numerous and
serious side-effects (McCurry and Ancoli-Israel, 2003; Yesavage et al., 2003).
Administration of melatonin to treat sleep disturbances in dementia has been
studied. Although results indicate that melatonin has minimal or no side-effects,
its efficacy in reducing disruptions in the rest–activity rhythm in AD patients
remains inconclusive, and two recent studies found it to be ineffective (Serfaty
et al., 2002; Singer et al., 2003).
Exposure of the eyes to light of adequate intensity and duration at the
appropriate time of day can have profound effects on the quality, duration and
timing of sleep. The effect of light on the circadian timing system is mediated by
the retinohypothalamic tract and the daily light–dark cycle is the primary syn-
chronizer responsible for entrainment of the sleep–wake rhythm to the 24-hour
day (Hoban et al., 1991). In an institutional environment where light levels tend
to be very low, residents may not be exposed to enough bright light to entrain
to the 24-hour day (Campbell et al., 1988; Shochat et al., 2000). Bright light
treatment has also been shown to ameliorate sleep–wake cycle disturbances in
some subjects with AD (Satlin et al., 1992).
The purpose of this study was to test the effect of morning bright light
exposure on nighttime sleep, daytime wake time, and the rest–activity rhythm.
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We hypothesized that administration of bright light treatment would improve
nighttime sleep (e.g. increase sleep efficiency, decrease the number of nighttime
awakenings), increase daytime wake time, and strengthen the rest–activity
rhythm.
Method
The 46 participants in this study were recruited from two large, long-term
care facilities in San Francisco, California. Staff from these facilities identified
residents who experienced rest–activity disruption and were diagnosed with AD.
Rest–activity disruptions included insomnia, frequent nighttime awakenings,
wandering at night, unusually early morning awakenings, “sundowning,” and
excessive daytime sleepiness. Chart reviews were conducted to confirm that
potential subjects met the following criteria for inclusion: a diagnosis of
AD according to the National Institute of Neurological and Communicative
Disorders and Stroke – the Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) criteria (McKhann et al., 1984), the ability
to perceive light, and a stable medication regimen. Potential subjects were
excluded if they had other neurological diagnoses (e.g. Parkinson’s disease) or
were regularly taking valerian, melatonin or sleeping pills. No subjects were
excluded on the basis of gender, race, or other medication usage. Informed
consent was obtained from responsible parties as approved by the Institutional
Review Board. Subjects were, on average, 84 years of age (SD = 10, range 60–98)
with a mean Mini-mental State Examination (MMSE; Folstein et al., 1975) score
of 6.7 (SD = 6.8, range 0–23). Seventy-eight percent of subjects were female and
22% male. The ethnic breakdown of the sample was: 80.4% Caucasian, 13.0%
African American, 4.4% Latino, and 2.2% Asian.
Rest–activity data were collected using the Actiwatch R© activity monitor
(AW-64, Mini Mitter Co. Inc., Bend, OR, U.S.A.). Actiwatches are compact,
wrist-worn, battery-operated activity monitors whose physical characteristics
are similar to a small wristwatch. These monitoring devices use a motion
sensor known as an “accelerometer” to monitor the occurrence and degree
of movement-induced accelerations. The sensor then integrates the degree and
speed of motion and produces a small signal whose magnitude and duration
depend on the amount of movement-induced accelerations. The signal is
amplified and digitized by the on-board circuit. This information is stored
in memory on board the device as activity counts in one-minute epochs.
Actiwatches were placed on each subject’s dominant wrist and a nylon locking
cable was affixed through the watchband to deter removal by the subject.
Subjects wore the Actiwatch continuously during each monitoring period.
224 G. A. Dowling et al.
Actigraph data have been shown to correlate well with polysomnography results
in healthy elderly people (Colling et al., 2000). Actigraphy provides a feasible
technique for studying the rest–activity rhythm in institutionalized patients with
dementia and correlates well with both electroencephalogram recordings and
direct observation (Ancoli-Israel et al., 1997; Singer et al., 2003).
This study was conducted in two phases. Phase One was designed to compare
morning bright light exposure with usual room light exposure; subjects were
randomly assigned to either the bright light or usual light conditions. Phase Two
was designed to compare morning with afternoon bright light exposure; subjects
were randomly assigned to either the morning bright light or afternoon bright
light conditions. Subjects exposed to morning bright light in both Phases One
and Two did not differ statistically on any demographic characteristics. We have
therefore included subjects who received morning bright light exposure in either
Phase One or Phase Two in these analyses.
The study protocol was 12 weeks in duration: baseline (week 1), intervention
(weeks 2–11), and postintervention (week 12). We report here on the variables
assessed at baseline (week 1) and during the last week of the 10-week intervention
period (week 11). Actigraphs were worn for six days and seven nights at baseline
and for five days and nights during the last week of the intervention. Subjects in
the experimental condition received one hour of bright light exposure (09:30–
10:30,> 2500 lux in gaze direction) Monday through Friday for 10 weeks. Study
staff who conducted activities for the experimental group worked closely with
recreational therapy departments at both locations to ensure that they were
appropriate for the patients and similar to those regularly scheduled. The
experimental group’s activities were held in a brightly lit area, either outdoors or
in an indoor space with expansive surrounding windows to let in ample amounts
of natural light. APOLLO Brite Lite IVTM (Orem, UT, U.S.A.) light boxes were
used, when necessary, to supplement the natural ambient light to ensure that
light in the gaze direction of the experimental group was at least 2500 lux. The
light boxes measured 23 × 12 × 4 inches and provided 10,000 lux exposure at
26 inches and 2500 lux exposure at 4 feet. Light levels were monitored each day
during the intervention with a Cal LIGHT 400TM (Auburn Hills, MI, U.S.A.)
calibrated precision light meter. The control group received usual indoor light
(150–200 lux) and participated in their regularly scheduled activities in their
usual location.
Actigraphy data were analyzed using the ActiwareTM Sleep Version 3.2
program. For the purposes of these analyses, nighttime was defined as 20:00
to 08:00 and daytime was defined as 08:00 to 20:00 as these times corresponded
to the institutional bed and rise times. Actual sleep and wake times were not
recorded as there was insufficient staff to observe and record these parameters
and the subjects were unable to use the event marker on the Actiwatches or
Light treatment for rest-activity in AD 225
accurately record in a diary. The primary outcome variables were sleep efficiency
(actual sleep time divided by the 12-hour nighttime period, and multiplied
by 100), nighttime sleep time, nighttime wake time, and number of nighttime
awakenings; daytime wake time was also examined.
Additional circadian outcomes were computed by two methods. Traditional
parametric cosinor analyses (Ancoli-Israel et al., 2002; Fontana Gasio et al.,
2003; Refinetti, 2000) and nonparametric techniques (Van Someren et al., 1999)
were used to estimate each subject’s 24-hour rest–activity rhythm.
For each subject and time condition, the parametric 24-hour fixed period
cosinor model was fit to the loge transformed actigraphy data (counts per
minute). Circular decimal clock time was re-represented as two trigonometric
dummy variables (sine and cosine projections on 06:00 and 24:00, respectively),
which were used as simultaneous independent variables in a least-squares
multiple regression. The decision to loge transform the raw count data prior
to analysis was based on the highly skewed empirical distribution of the activity
count data, and also was intended to ensure a larger relative weighting of the
fit to the conceptually important lower activity nocturnal period. The loge
transformation makes the effective data analysis weight-of-evidence for each
time point more uniform and balanced over the entire 24-hour period.
The resulting within-subject coefficient estimates were then transformed to
compute standard interpretive cosinor parameters (e.g. amplitude, acrophase)
as well as a goodness-of-fit index for the model (R2). These within-subject
cosinor summary parameters then became variables in the across-subject
analyses.
The cosinor model is a simple, effective and robust first-order description
of the average level, magnitude of swing, and general timing of a subject’s
diurnal activity pattern. However, the model may be too simple to capture
some important qualitative aspects of the 24-hour activity patterns. In particular,
the model presumes a simple cosinusoidal shape to the 24-hour pattern, with
a 12-hour:12-hour cycle, and an exact 12-hour difference between the peak
acrophase and the nadir. Adult human activity patterns tend to have a cycle that
is more like 16-hours:8-hours, an average shape that looks more like a square
wave than a pure cosinuoid, and no formal constraint on the relative timing of
acrophase and nadir. Thus, in addition to considerable random components to
the residual variance of the cosinor model that are related to the minute-by-
minute fluctuations in measured activity counts, there may also be substantial
structural model mismatch error forced into the overall error term. The fitted
acrophase becomes a compromise between the timing of the true activity peak
and nadir, which may not be an efficient representation of either. The activity
levels that are predicted by the fitted cosinor model may significantly overestimate
the true average levels measured during the typically shorter sleep/rest period.
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This motivates the addition of other summary measures that are more sensitive
to the characteristics of the empirical 24-hour activity profile.
Nonparametric techniques were used to assess the following circadian
parameters (Van Someren et al., 1999):
a) interdaily stability (IS) – quantifies the degree of resemblance between activity patterns
of individual days, theoretical range of 0–1, higher values indicate a more stable
rhythm;
b) intradaily variability (IV) – quantifies the fragmentation of periods of rest and activity,
theoretical range near 0 for a sine wave up to 2 for Gaussian noise and even higher
values when a definite ultradian component with a period of 2 hours is present, higher
values indicate a more fragmented rhythm;
c) L5 – sequence of the five least active hours in the 24-hour average activity profile.
Average activity during L5 provides an indication of trough or nadir of the rhythm
(i.e. regularity and restfulness of sleep periods), lower values indicate more restful
sleep;
d) M10 – sequence of the 10 most active hours in the 24-hour average activity profile.
Average activity during M10 provides an indication of the peak of the rhythm, that is
how active and regular the activity (wake) periods are;
e) relative amplitude (RA) – reflects the normalized difference between the most active
10-h period and the least active 5-hour period in an average 24-hour pattern,
theoretical range from 0 to 1, higher values indicate a stronger rhythm.
Results
Compliance with actigraphy
Subjects tolerated the Actiwatches R© well, with 84% never removing the device
during the 12-day monitoring period (six days and seven nights at baseline and
five days and nights during the last week of the intervention). On average, there
were 152 hours of valid data for the baseline assessment (SD = 9, range 125–
156) and 105 hours of valid data for the end of intervention assessment (SD = 7,
range 69–108).
Exposure to light treatment
Exposure to at least 2500 lux during the intervention was assured by daily
light meter readings, which yielded a mean of 7500 lux (SD = 9500; range
2500–65 500). Total exposure to the light treatment was recorded for each
patient and reflected absence due to illness or holiday, and approximate percent
of the intervention missed (eyes closed/sleeping, toileting time, etc.). The
percentage of exposure to the light treatment was calculated by dividing the
hours of intervention received by the total possible number of intervention hours
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(50 hours over the 10-week intervention period). The mean exposure to the light
treatment over the entire intervention period was 73% (SD = 17.5, range 28–98).
Nighttime sleep
Mean values for the nighttime sleep variables by group are presented in Table 1.
Using an intent-to-treat analysis, where all subjects who were randomized were
included in the analyses, repeated measures analysis of variance (ANOVA)
revealed no significant changes in sleep efficiency, sleep time, wake time, or
number of awakenings in the experimental group as compared to the control
group.
Daytime wake time
Mean values for the daytime wake time by group are presented in Table 1. There
was no significant difference between the experimental and control groups on
daytime average wake time.
Circadian rhythms
Cosinor analyses of baseline data revealed relatively low R2 values (see Table 1)
indicating a poor goodness of fit of this model with the data. Figure 1 illustrates
the distribution of the cosinor parameters during week 1 and Figure 2 for
week 11. In these polar plots, the acrophase is represented on the angular axis
with 0 representing midnight, 6 representing 06:00, 12 representing 12:00 noon,
and 18 representing 18:00. The rhythm amplitude is depicted by the position
on the radial axes. There were no significant differences in R2, amplitude, or
acrophase between the groups. There was a trend (p< 0.09) toward significance
in amplitude with improvement in the experimental group and worsening in
the control group. There was also a trend (p< 0.08) toward significance in the
rest–activity acrophase. The average peak of the rest–activity rhythm delayed in
the control group from 13:32 to 15:34 (122 minutes) and advanced slightly in
the experimental group from 15:29 to 15:25 (4 minutes). There were also no
significant differences in the intent-to-treat analyses between groups on variables
derived from the nonparametric circadian rhythm analyses (i.e. IS, IV, L5, M10,
or RA).
There was a wide variability in L5 onset times at baseline as illustrated in
Figure 3, where position on the angular axis corresponds to clock time. L5
is an indication of the rest–activity nadir and defined as the five least active
hours in the 24-h average curve (Van Someren et al., 1999). Thus, the optimal
timing of the five least active hours would be during bedtime. In this study, the
usual institutional bedtime was 20:00 and rise time was 08:00. During post-
hoc analysis, we therefore categorized subjects into two groups based on L5
onset time. Non-aberrant onset times were defined as those between 20:00 and
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Table 1. Means and standard deviations for actigraphy measured nighttime and
daytime variables, parametric cosinor and nonparametric analyses of rest–activity
rhythm data; n= 46 (17 control, 29 experimental)
B A S E L I N E E N D O F I N T E R V E N T I O N
(W E E K 1) (W E E K 11)
.............................................................................................................................................................................................................................................
NIGHTTIME
Sleep efficiency
Control 66.88 (19.24) 71.14 (16.78)
Experimental 63.02 (19.57) 66.64 (15.85)
Sleep time (hours:minutes)
Control 8:01 (2:18) 8:32 (2:00)
Experimental 7:33 (2:20) 7:59 (1:54)
Wake time (hours:minutes)
Control 3:58 (2:18) 3:27 (2:00)
Experimental 4:25 (2:20) 3:59 (1:54)
Number of awakenings
Control 34.88 (13.65) 37.99 (11.65)
Experimental 41.56 (16.03) 42.88 (16.63)
DAYTIME
Day wake time (hours:minutes)
Control 7:21 (2:43) 6:34 (2:50)
Experimental 6:36 (2:30) 6:24 (2:38)
COSINOR
R2
Control 0.17 (0.14) 0.16 (0.13)
Experimental 0.09 (0.09) 0.11 (0.09)
Amplitude
Control 1.32 (0.83) 1.20 (0.79)
Experimental 0.89 (0.56) 1.05 (0.70)
Acrophase (hours:minutes)
Control 13:32 (2:37) 15:34 (3:40)
Experimental 15:29 (3:19) 15:25 (4:40)
NONPARAMETRIC
Interdaily stability (IS)
Control 0.47 (0.18) 0.51 (0.15)
Experimental 0.36 (0.16) 0.47 (0.18)
Intradaily variability (IV)
Control 1.17 (0.45) 1.20 (0.34)
Experimental 1.27 (0.35) 1.33 (0.32)
L5
Control 40.75 (49.20) 27.18 (33.79)
Experimental 61.27 (99.24) 38.72 (62.33)
M10
Control 149.22 (103.74) 133.42 (108.16)
Experimental 182.32 (302.25) 221.20 (541.13)
Relative amplitude (RA)
Control 0.62 (0.21) 0.68 (0.15)
Experimental 0.52 (0.22) 0.59 (0.22)
L5 = sequence of the five least active hours in the 24-hour average activity profile; M10 = sequence of the
10 most active hours in the 24-hour average activity profile.
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Figure 1. Cosinor-derived rest–activity acrophase (peak) and amplitude at week 1 illustrates marked
between-subject variability. Position on the angular axis corresponds to clock time, position on the
radial axis corresponds to amplitude.
03:00 and aberrant times as between 03:01 and 19:59. Using this definition, 13
subjects were aberrant (n= 11 experimental, n= 2 control) and 33 subjects were
non-aberrant (n= 18 experimental, n= 15 control). Paired t-tests on data from
subjects in the experimental group with aberrant L5 onset times at baseline
demonstrated a significant improvement in IS (p< 0.02) and a trend toward
increased RA (p< 0.08) at the end of intervention compared to baseline. Paired
t-tests on data from subjects in the experimental group with non-aberrant L5
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Figure 2. Cosinor-derived activity acrophase (peak) and amplitude at week 11 illustrates persistent
between-subjects variability. Position on the angular axis corresponds to clock time, position on the
radial axis corresponds to amplitude.
onset times at baseline demonstrated a significant worsening in IV (p< 0.05)
at the end of intervention compared to baseline. There were no significant
improvements in the experimental non-aberrant group or either aberrant or
non-aberrant control group subjects.
Similarly, there was a wide variability in M10 onset times at baseline as
illustrated in Figure 4, where position on the angular axis again corresponds to
clock time. M10 is an indication the rest–activity peak and defined as the 10 most
active hours in the 24-hour average curve (Van Someren et al., 1999). Optimal
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Figure 3. Polar plot illustrates mean time of onset for the ﬁve least active hours in the 24-hour day
during week 1. Position on the angular axis corresponds to clock time. Onset times between 03:01 and
19:59 are deﬁned as aberrant.
timing of peak activity would be during the day, with possibly some overlap
into the 12-hour institutionally defined “night” of 20:00 to 08:00. Subjects
were again categorized into two groups based on their M10 onset time. Non-
aberrant onset times were defined as those between 06:00 and 12:00 and aberrant
times between 12:01 and 05:59. Using this definition, 17 subjects were aberrant
(n= 12 experimental, n= 5 control) and 29 subjects were non-aberrant (n= 17
experimental, n= 12 control). Seven subjects in the experimental group and
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Figure 4. Polar plot illustrates mean time of onset for the 10 most active hours in the 24-hour day
during week 1. Position on the angular axis corresponds to clock time. Onset times between 12:01 and
05:59 are deﬁned as aberrant.
two in the control group had both aberrant M10 onset and L5 onset times.
Paired t-tests on data from subjects in the experimental group with aberrant
M10 onset times demonstrated a significant improvement in IS (p< 0.002), RA
(p< 0.05), nighttime sleep efficiency (p< 0.03), nighttime sleep time (p< 0.03),
and nighttime wake time (p< 0.03) at the end of intervention compared to
baseline. There were no significant improvements in the experimental non-
aberrant group or either aberrant or non-aberrant control group subjects.
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However, in the control non-aberrant group, there was a trend (p< 0.06) toward
a decrease in daytime wake time.
Discussion
Our morning bright light exposure protocol did not induce an overall
improvement in measures of sleep or the rest–activity rhythm in all experimental
as compared to control subjects in the intent-to-treat analyses. Our original
purpose in this study was to expose subjects to natural sunlight, but during
the course of the study several issues arose. Because of institutional staffing
constraints, subjects in the experimental condition were only exposed to bright
light Monday through Friday as there was not enough staff to transport the
subjects to the bright light condition and engage them in activities to keep them
awake with their eyes open on the weekends. It is possible that subjects would
have experienced a more robust circadian effect with daily light exposure or
exposure of longer duration each day. In addition, there was insufficient natural
light on some days to increase the ambient light to our threshold definition of
≥ 2500 lux. We therefore had to supplement the natural light with light boxes to
ensure subjects received adequate light exposure.
The most significant improvements were found in the subjects with
desynchronized timing of their rest–activity rhythm. Those who experienced
their 10 most active hours during the typical hours of sleep at baseline improved
their rhythm stability from day-to-day; the difference between their least active
and most active periods was strengthened; and sleep efficiency, night sleep and
wake times were improved at the end of the intervention.
For both the control and experimental groups, nighttime sleep and daytime
wake variables were improved at the week 11 assessment. This observation
is consistent with the outcomes of our repeated measures ANOVA, which
demonstrated numerous trends or significant main effects of time. Rest–activity
disruption was a criteria for inclusion in the study and regression to the mean is
very likely to be operating in the data. However, using the randomized pre-post
test design with a control group, the regression to the mean phenomena should
equally bias experimental and control groups.
The subjects in this study had fairly severe AD with an overall average
MMSE score of 6.7 (SD = 6.8, median = 5, range 0–23) and a mean age of
84 years (median = 88, range 60–98). Their rest–activity rhythms were severely
disrupted, as reflected by low values for R2 (mean = 0.12) and stability (mean
IS = 0.4), high variability (mean IV = 1.2), and low relative rhythm amplitude
(RA = 0.56). In addition, there was significant activity during the defined night as
reflected by a high L5 (mean = 54). These findings are similar to those reported
by Van Someren and colleagues (1996) in their institutionalized subjects with
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dementia who were more impaired on these parameters than control subjects
or community dwelling subjects with dementia. Their institutionalized subjects
with dementia were also exposed to less light than other subjects and responded
to 4 weeks of indirect all-day bright light with increased rhythm stability
(Van Someren et al., 1997). Light also significantly improved rhythm stability
(IS) in our subjects, who had aberrant L5 onset times at baseline and trended
towards strengthening the rest–activity rhythm as evidenced by an increase in
RA. Light also resulted in significant improvements in IS and RA in subjects with
aberrant M10 onset times at baseline. Furthermore, there was an improvement in
nighttime sleep time, nighttime wake time, and sleep efficiency in these subjects.
These data suggest that subjects with the most impaired rest–activity rhythms
responded positively to the light intervention.
The phase delay of the acrophase of the rest–activity rhythm reported by
Ancoli-Israel and colleagues (2002) after exposure of their subjects to morning
light was not seen in our sample. However, our subjects had more severe AD
(mean MMSE = 6.7) than their subjects (mean MMSE = 12.8) and it is possible
that circadian rhythms respond to light differently across the range of cognitive
impairment. Our patients with AD were generally poorly entrained to the
24-hour light–dark cycle and tended to phase delay without bright morning
light (i.e. control group). Perhaps the experimental group, as a whole, received
sufficient additional light to prevent them from phase shifting but not enough to
impact other circadian or sleep parameters. And, as described above, the most
severely impaired subjects exhibited significant responses.
There was substantial inter- and intraindividual variability in our sample.
As noted above, many of our subjects exhibited their 10 most active hours or
five least active hours at times other than would be expected based upon the
light–dark cycle and institutional routine. It is highly likely that some subjects
received the light intervention at an insensitive part of their phase response curve
depending on their endogenous time. Or perhaps subjects with dementia have
an altered phase response curve to light.
Subjects with the most impaired rest–activity rhythm responded significantly
and positively to a one-hour bright light intervention, delivered five days a
week for 10 weeks. Bright light remains a potentially promising and practical
intervention in the long-term care environment. Further studies are needed to
assess whether daily and longer duration of light exposure could produce more
robust effects.
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